| |
2009 - 2008 - 2007 - 2006 - 2005 - 2004 - 2003 - 2002 - 2001 - 2000 - 1999 - 1998 - 1997
2009 Academic Year
Articles and book chapters
Gauthier S. Pharmacology of Parkinson Disease Dementia and Lewy Body dementia. In “Dementia in Clinical Practice”, Giannakopoulos P, Hof P [Eds], Frontiers in Neurology and Neuroscience, Vol 24. Karger, 135-139, 2009. MEDLINE link to this publication
Gauthier S. Dimebon improves cognitive function in people with mild to moderate Alzheimer’s disease. Evidence Based Mental Health, 12, 21, 2009. MEDLINE link to this publication
Erkinjuntti T, Gauthier S.The concept of Vascular Cognitive Impairment. In “Dementia in Clinical Practice”, Giannakopoulos P, Hof P [Eds], Frontiers in Neurology and Neuroscience, Vol 24. Karger, 79-85, 2009. MEDLINE link to this publication
Robert P, Onyike C, Leentjens A, Dujardin K, Aalten P, Starkstein S, Verhey F, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorea PM, Thibault F, Cummings J, Gauthier S, Grossberg G, Vellas B, Byrne J. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. European Psychiatry, 24, 98-104, 2009. MEDLINE link to this publication
Andrieu S, Coley N, Aisen P, Carrillo M, Dekosky S, Durga J, Fillit H, Frisoni G, Froelich L, Gauthier S, Jones R, Jonsson L, Khachaturian Z, Morris J, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. Journal of Alzheimer’s Disease, 16, 235-270, 2009. MEDLINE link to this publication
Saumier D, Aisen P, Gauthier S, Vellas B, Ferris SH, Duong A, Suhy J, Oh J, Lau W, Garceau D, Haine D, Sampalis J. Lessons learned in the use of volumetric MRI in therapeutic trials in Alzheimer’s disease: the Alzhemed (tramiprosate) experience. Journal of Nutrition Health & Aging, 13, 370-372, 2009. MEDLINE link to this publication
Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, Frank RA, Holzapfel A, Khachaturian AS, Korczyn AD, Roses A, Simpkins JW, Schneider LS, Albert MS, Egge R, Deves A, Ferris S, Greenberg BD, Johnson C, Kukull WA, Poirier J, Schenk D, Thies W, Gauthier S, Gilman S, Bernick C, Cummings JL, Fillit H, Grundman M, Kaye J, Mucke L, Reisberg B, Sano M, Pickeral O, Petersen RC, Mohs RC, Carrillo M, Corey-Bloom JP, Foster NL, Jacobsen S, Lee V, Potter WZ, Sabbagh MN, Salmon D, Trojanowski JQ, Wexler N, Bain LJ. A roadmap for the prevention of dementia II: Leon Thal symposium 2008. Alzheimer’s & Dementia, 5, 85-92, 2009. MEDLINE link to this publication
Gauthier S, Poirier J. Commentary on “A roadmap for the prevention of dementia II. Leon Thal Symposium 2008”. Who may benefit from disease-modifying studies in Alzheimer’s disease? Alzheimer’s & Dementia, 5, 147-148, 2009. MEDLINE link to this publication
Villeneuve S, Belleville S, Massoud F, Bocti C, Gauthier S. The impact of vascular risk factors and diseases on cognition in persons with mild cognitive impairment. Dementia and Geriatric Cognitive Disorders, 27, 375-381, 2009. MEDLINE link to this publication
Hudon C, Belleville S, Gauthier S. The assessment of recognition memory using the remember/know procedure in amnestic mild cognitive impairment and probable Alzheimer’s disease. Brain and Cognition,
70, 171-179, 2009. MEDLINE link to this publication
Ballard C, Gauthier S, Cummings J, Brodaty H, Grossberg G, Robert P, Lyketsos C. Management of agitaton and aggression associated with Alzheimer’s disease. Nature Reviews - Neurology, 5, 1-11, 2009. MEDLINE link to this publication
Gauthier S, Aisen PS, Ferris SH, Saumier D, Duong A, Haine D, Garceau D, Suhy J, Oh J, Lau W, Sampalis J for the ALPHASE group. Effect of tramiprosate in patients with mild-to-moderate Alzheimer’s disease: exploratory analyses of the MRI sub-group of the ALPHASE study. Journal of Nutrition, Health and Aging, 13, 550-557, 2009. MEDLINE link to this publication
Gauthier S, O'Brien J. Top cited papers in international psychogeriatrics: 3. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2009 Jun;21(3):454-6. Epub 2009 Apr 16. MEDLINE link to this publication
Gauthier S. Will CSF analysis become routine in people with memory complaints? Lancet Neurol. 2009 Jul;8(7):595-6. Epub 2009 Jun 10. MEDLINE link to this publication
Rolleston F, Corman J, Gauthier S, O’Hara P, Schmaltz R. Ethics issues with private research ethics boards: a breakout session at the 2009 NCEHR National Conference. Journal of Academic Ethics, DOI 10.1007/s10805-009-9084-1., published online 28 July 2009.
Ferris S, Inl R, Robert P, Winblas B, Gatz G, Tennigkeit F, Gauthier S. Severe Impairment Battery Language scale: a language-assessment tool for Alzheimer’s patients. Alzheimer’s & Dementia, 5, 375-379, 2009. MEDLINE link to this publication
Ferris S, Ihl R, Robert P, Winblad B, Gatz G, Tennigkeit F, Gauthier S. Treatment effects of memantine on language in moderate to severe Alzheimer’s patients. Alzheimer’s & Dementia, 5, 369-374, 2009. MEDLINE link to this publication
Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones R, Gauthier S, Lopez O, Cummings J, Xu Y, Feldman H. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders, 28, 244-251, 2009. MEDLINE link to this publication
Gauthier S, Scheltens P. Can we do better in developing new drugs for Alzheimer’s disease? Alzheimer’s & Dementia, 5, 489-491, 2009. MEDLINE link to this publication
Gauthier S. Psychopharmacology for the clinician: should we treat patients with verymild Alzheimer disease with acholinesterase inhibitor?.
Journal of Psychiatry & Neuroscience, 34, 480, 2009. MEDLINE link to this publication
Plosker GL, Gauthier S. Cerebrolysin. A review of its use in dementia. Drugs Aging 26, 893-915, 2009. MEDLINE link to this publication
Suh Guk-Hee, Wimo A, Gauthier S, O’Connor D, Ikeda M, Homma A, Dominguez J, Yang BM. International price comparisons for the Alzheimer drugs: a way to close the affordability gap. International Psychogeriatrics, 21, 1116-1126, 2009. MEDLINE link to this publication
Brambati SM, Belleville S, Kergoat MJ, Chayer C, Gauthier S, Joubert S. Single – and multiple-domain amnestic mild cognitive impairment: two sides of the same coin? Dementia and Geriatric Cognitive Disorders 28, 541-549, 2009. MEDLINE link to this publication
Gauthier S. Innovations thérapeutiques dans la maladie d’Alzheimer. Revue de Gériatrie, 34 (Suppl B), B15-B16, 2009.
Gauthier S, Leuzy A. Diagnosis of prodromal Alzheimer’s disease: do you really want to know? Canadian Journal of Neurological Sciences, 37, 2, 2010. MEDLINE link to this publication
Davidson JE, Irizarry MC, Bray BC, Wetten S, Galwey N, Gibson R, Borrie M, Delisle R, Feldman HH, Hsiung GY, Fornazzari L, Gauthier S, Guzman D, Loy-English I, Keren R, Kertesz A, George-Hyslop PS, Wherrett J, Monsch AU. An exploration of cognitive subgroups in Alzheimer’s disease. Journal of the International Neurological Society, 2009 Dec 4 [Epub ahead of print]. MEDLINE link to this publication
Black S, Gauthier S, Dalziel W, Keren R, Correira J, Hew H, Binder C. Canadian Alzheimer’s disease caregiver survey: baby-boomer caregivers and burden of care. International Journal of Geriatric Psychiatry, 2009 Dec 22 [Epub ahead of print], doi 10.1002/gps.2421. MEDLINE link to this publication
Published abstracts
Gauthier S. Diagnosis of Alzheimer’s disease in its pre-dementia stage. Journal of Nutrition, Health & Aging, 13, 63, 2009.
Gauthier S. How a consensus was reached between family doctors and specialists towards diagnosis and treatment. Journal of Nutrition, Health & Aging, 13, 72, 2009.
Gauthier S, Aisen P, Ferris S, Garceau D, Saumier D, Duong A, Sampalis J. A Phase III, placebo-controlled, double-blind randomized trial assessing the effect of tramiprosate on hippocampus volume changes in patients with mild-to-moderate Alzheimer’s disease (the Alphase Study). Neurology 72 (Suppl 3), A246-247, 2009.
Aisen P, Gauthier S, Ferris S, Garceau D, Saumier D, Duong A, Sampalis J. A Phase III, placebo-controlled, double-blind randomized trial of tramiprosate in the clinical management of patients with mild-to-moderate Alzheimer’s disease (the Alphase Study). Neurology 72 (Suppl 3), A271, 2009.
Gauthier S, Lopez O, Schwam E, Waldemar G, Jones R, Wilkinson D, Zhang R, Schindler R. Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer’s disease. Neurology 72 (Suppl 3) A301-302, 2009.
Gauthier S. Ethical considerations. Journal of Nutrition, Health & Aging, 13, S20, 2009.
Gauthier S. Treatment of apathy and neuropsychiatric symptoms in Alzheimer disease. Journal of Nutrition, Health & Aging, 13, S32, 2009.
Gauthier S, Lopez O, Schwam E, Waldemar G, Jones R, Wilkinson D, Zhang R, Schindler R. Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer’s disease. Journal of Nutrition, Health & Aging, 13, S397, 2009.
Winblad B, Gauthier S. Memantine shows bebeficial effects on functional abilities in moderate-to-severe Alzheimer’s disease. Journal of Nutrition, Health & Aging, 13, S401, 2009.
Minuzzi L, Quirion R, Gauthier S, Rosa-Neto P. Declines of hippocampal metabotropic glutamate receptors in Alzheimer’s disease. Alzheimer’s & Dementia, 5 (Suppl 1), P56, 2009.
Robert P, Ferris S, Gauthier S, Gatz G, Winblad B, Tennigkeit F. The need for a new practical Alzheimer Disease practical scale. Alzheimer’s & Dementia, 5 (Suppl 1), P186, 2009.
Gauthier S. Methodological issues for preventive trials. Alzheimer’s & Dementia, 5 (Suppl 1), P142, 2009.
Reisberg B, Gauthier S, Shulman M, Torossian C, Zhu W, Boksay I, Monteiro I, Prichep L, Mosconi L, Vedvyas A, Jamil I, De Leon M. Subjective Cogntive Impairment: the pre-MCI stage of AD: antecedents and consequences. International Psychogeriatrics, 21 (Suppl 2), S15, 2009.
De Medeiros K, Robert P. Gauthier S, Stella F, Politis A, Taragano F, Kremer J, Brugnolo A, Porsteinsson A, Geda Y, Brodaty H, Lyketsos C. The NPI-C: a clinician-rated assessment of neuropsychiatric symptoms in dementia. International Psychogeriatrics, 21 (Suppl 2), S92-93, 2009.
Gauthier S. New criteria for Alzheimer’s disease including “predementia”. Journal of the Neurological Sciences, 285 (Suppl 1), S40, 2009.
Rosa-Neto P, Rowley J, Shoemaker D, Van Noort B, Kandratavicius L, Minuzzi L, Gauthier S. Declines of metabotropic glutamate receptors in patients with early AD: in vivo evidence of a novel biomarker for hippocampal dysfunction. Neurology 74 (Suppl 2), A487, 2010.
Books and Educational Material
Vascular Cognitive Impairment in Clinical Practice. Wahlund LO, Erkinjuntti T, Gauthier S (Eds), Cambridge University Press, Cambridge, 2009.
Management of Dementia. Gauthier S, Ballard C. Informa Healthcare, London, 2009 (2nd Edition)
2008 Academic Year
Articles:
Li H, Wetten S, Li L, St Jean PL, Upmanyu R, Surh L, Hosford D, Barnes MR, Briley JD, Borrie M, Coletta N, Delisle R, Dhalla D, Ehm MG, Feldman H, Fornnazzari L, Gauthier S, Goodgame N, Guzman D, Hammond S, Hollingworth P, Hsiung GY, Johnson J, Kelly DD, Keren R, Kertesz A, King KS, Lovestone S, Loy-English I, Matthews PM, Owen MJ, Plumpton M, Pryse-Phillips W, Prinjha RK, Richardson JC, Saunders A, Slater AJ, St George-Hyslop PH, Stinnett SW, Swartz JE, Taylor RL, Wherrett J, Williams J, Yarnall DP, Gibson RA, Irizarry MC, Middleton LT, Roses AD. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer’s disease. Archives of Neurology 65, 45-53, 2008. MEDLINE link to this publication
Gauthier S. Trial designs and outcomes to monitor novel therapeutics in Alzheimer’s disease. In Pharmaceutical and Mechanisms in Alzheimer’s Therapeutics, AC Cuello [Ed], Springer, New York, 28-35, 2008.
Clément F, Belleville S, Gauthier S. Cognitive complaint in mild cognitive impairment and Alzheimer’s disease. Journal of the International Neuropsychological Society,14, 222-232, 2008. MEDLINE link to this publication
Reisberg B, Gauthier S. Current evidence for subjective cognitive impairment (SCI) as the pre mild cognitive impairment (MCI) stage of subsequently manifest Alzheimer’s disease. International Psychogeriatrics, 20, 1-16, 2008. MEDLINE link to this publication
Gauthier S, Loft H, Cummings J. Improvement in behavioral symptoms in patients with moderate to severe Alzheimer’s disease by memantine: a pooled data analysis. International Journal of Geriatric Psychiatry, 23, 537-545, 2008. MEDLINE link to this publication
Poirier J, Gauthier S. Pharmacogenomics and the treatment of sporadic Alzheimer’s disease: a decade of progress. Current Pharmacogenomics and Personalized Medicine, 6, 63-76, 2008.
Gauthier S, Poirier J. Current and future management of Alzheimer’s disease. Alzheimer’s & Dementia, 4 (suppl 1), S48-S50, 2008. MEDLINE link to this publication
Hsiung GYR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, Feldman H. Transitions from Cognitively Impaired Not Demented to Alzheimer’s disease: an analysis of changes in functional abilities in a dementia clinic cohort. Dementia & Geriatric Cognitive Disorders, 25, 483-490, 2008.
Erkinjuntti T, Gauthier S, Bullock R, Kurz A, Hammond G, Zhu Y, Brashear R, Schwalen S. Galantamine treatment in Alzheimer’s disease with cerebrovascular disease: responder analysis from a randomized, controlled trial (GAL-INT-6). Journal of Psychopharmacology, 25 Feb 2008, PMID 18308781. MEDLINE link to this publication
Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Wang D, Brashear HR, Nye JS and the GAL-INT-11/18 Study group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, 22, 2024-2035, 2008. MEDLINE link to this publication
Gauthier S. Symptomatic therapeutic aspects in Alzheimer’s disease. In “Dementias”. Handbook of Clinical Neurology, vol 89 (3rd series), C. Duyckaerts & I. Litvan, Eds, Elsevier, 269-271, 2008. MEDLINE link to this publication
Hudon C, Belleville S, Gauthier S. The association between depressive and cognitive symptoms in amnestic mild cognitive impairment. International Psychogeratrics, 20, 710-723, 2008. MEDLINE link to this publication
Gauthier S, Dubois B, Feldman H, Scheltens P. Status report on the revised research diagnostic criteria for Alzheimer’s disease. Lancet Neurology, 7, 668-670, 2008. MEDLINE link to this publication
Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, Filit H, Foster N, Greenberg B, Grundman M, Sano M, Simpkins J, Schneider LS, Weiner MW, Galasko D, Hyman B, Kuller L, schenk D, Snyder S, Thomas RG, Tuszyynski MH, Velas B, Wurtman RJ, Snyder PJ, Frank RA, Albert M, Doody R, Ferris S, Kaye J, Koo E, Morrison-Bogorad M, Reisberg B, Salmon DP, Gilman S, Mohs R, Aisen PS, Breitner JC, Cummings JL, Kawas C, Phelps C, Poirier J, Sabbah M, Touchon J, Khachaturian AS, Bain LJ. A roadmap for the prevention of dementia: the inaugural Leon Thal Symposium. Alzheimer’s & Dementia, 4, 156-163, 2008. MEDLINE link to this publication
Peters KR, Rockwood K, Black SE, Hogan DB, Gauthier S, Loy-English I, Hsiung GY, Jacova C, Kertesz A, Feldman HH. Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. Amerian Journal of Geriatric Psychiatry, 16, 136-144, 2008. MEDLINE link to this publication
Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone P, Weintraub D, Tolosa E, Dubois B. Diagnosis and management of Parkinson’s disease dementia. International Journal of Clinical Practice, 62, 1581-1587, 2008. MEDLINE link to this publication
Letenneur L, Pérès K, Fleury H, Garrigue I, Barberger-Gateau P, Helmer C, Orgogozo JM, Gauthier S, Dartigues JF. Seropositivity to Herpes Simplex virus antibodies and risk of Alzheimer’s disese: a population-based cohort study. PlosOne, 3, e3637, Epub Nov 4th 2008. MEDLINE link to this publication
Herrmann N, Gauthier S. Management of severe Alzheimer’s disease. Canadian Medical Association Journal, 179, 1279-1297, 2008.
Belleville S, Bherer L, Lepage E, Chertkow H, Gauthier S. Task switching capacities in persons with Alzheimer’s disease and mild cognitive impairment. Neuropsychologia, 46, 2225-2233, 2008. MEDLINE link to this publication
Gauthier S. Pharmacotherapy of Alzheimer’s disease. Current and future perspectives. European Pharmacotherapy, in press.
Erkinjunntti T, Roman G, Gauthier S. Treatment of vascular dementia – evidence from clinical trials with cholinesterase inhibitors. J Neurological Sciences, in press.
Berdugo B, Gauthier S. Utilisation des timbres cutanés dans la maladie d’Alzheimer, une nouvelle approche galénique. Le Pharmacien, in press.
Gauthier S. Pharmacology of Parkinson Disease Dementia and Lewy Body dementia. In “Dementia in Clinical Practice”, Giannakopoulos P, Hof P [Eds], Frontiers in Neurology and Neuroscience, Karger, in press.
Robert P, Onyike C, Leentjens A, Dujardin K, Aalten P, Starkstein S, Verhey F, Yessavage J, Clement JP, Drapier D, Bayle F, Benoit M, Boyer P, Lorea PM, Thibault F, Cummings J, Gauthier S, Grossberg G, Vellas B, Byrne J. Proposed diagnostic criteria for apathy in Alzheimer’s disease and other neuropsychiatric disorders. European Psychiatry, in press.
Andrieu S, Coley N, Aisen P, Carrillo M, Dekosky S, Durga J, Fillit H, Frisoni G, Froelich L, Gauthier S, Jones R, Jonsson L, Khachaturian Z, Morris J, Orgogozo JM, Ousset PJ, Robert P, Salmon E, Sampaio C, Verhey F, Wilcock G, Vellas B. Methodological issues in primary prevention trials for neurodegenerative dementia. Journal of Alzheimer’s Disease, in press.
Gauthier S. Top cited papers in International Psychogeriatrics: efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Reflection. International Psychogeriatrics, in press.
Erkinjuntti T, Gauthier S. The concept of vascular cognitive impairment. In “Dementia in Clinical Practice”, Giannakopoulos P, Hof P [Eds], Frontiers in Neurology and Neuroscience, Karger, in press.
Hudon C, Belleville S, Gauthier S. Recognition memory in amnestic mild cognitive impairment and Alzheimer’s disease is characterized by impaired recollection but normal familiarity. Journal of Clinical and Experimental Neuropsychology, submitted.
Suh GH, Wimo A, OÇonor D, Gauthier S, Ikeda M, Homma A, Dominguez J, Yang BM. International price comparisons for the Alzheimer’s drugs: how to afford the affordability gap? Bulletin of the World Health Organization, submitted.
Wilkinson D, Schindler R, Schwam E, Waldemar G, Jones R, Gauthier S, Lopez O, Cummings J, Xu Y, Feldman H. Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate Alzheimer’s disease. Archives of Neurology, submitted.
Gauthier S, Poirier J. Who may benefit from disease-modifying treatments in Alzheimer’s disease? Alzheimer’s & Dementia, submitted.
Bélanger S, Belleville S, Gauthier S. Inhibition impairments in Alzheimer’s disease, Mild Cognitive impairment and healthy aging: effect of congruency proportion in a Stroop task. Neuropsychologia, submitted.
Published Abstracts
Gauthier S. Management of behavioural problems in Alzheimer’s disease. Neurobiology of Aging, 29, S9-S10, 2008.
Bocti C, Belleville S, Labelle MA, Massoud F, Gauthier S. The value of the HIV dementia scale in vascular mild cognitive impairment. Alzheimer’s & Dementia, 4 (Suppl 2), T252, 2008.
Fokkens J, Ferris S, Robert P, Winblad B, Gauthier S. development of a language assessment tool for patients with Alzheimer’s disease. Alzheimer’s & Dementia, 4 (Suppl 2), T519, 2008.
Gauthier S, Guuilhaume-Goulan C, Rive B. Memantine decreases and prevent the emergence of key behavioral symptoms of Alzheimer’s disease. Alzheimer’s & Dementia, 4 (Suppl 2), T764-765, 2008.
Kokkens J, Ferris S, Robert P, Winblad B, Gauthier S. Assessment of memantine treatment effects on language. Alzheimer’s & Dementia, 4 (Suppl 2), T780-781, 2008.
Gauthier S, Lopez O, Schwam E, Feldman H, Waldemar G, Jones RW, Wilkinson D, Zhang R, Schindler R. Impact of donepezil therapy on function in relation to MMSE in patients with Alzheimer’s disease. Alzheimer’s & Dementia, 4 (Suppl 2), T781, 2008.
Gauthier S, Douillet P, Doody R, Fox NC, Orgogozo JM for the Xaliprodem AD Study Team. Effect of xaliprodem, a compound with neurotrophic properties, on the progression of Alzheimer’s disease. Results of two large 18-month studies assessing clinical efficacy and cerebral atrophy. Journal of Nutrition, Health & Aging, 12, 538, 2008.
Books and Educational Material
Vascular Cognitive Impairment in Clinical Practice. Wahlund LO, Erkinjuntti T, Gauthier S (Eds), Cambridge University Press, Cambridge, 2008 (in press).
2007 Academic Year
Articles:
Dubois B, Burn D, Goetz C, Aarsland D, Brown R, Broe A, Dickson D, Duyckaerts C, Cummings J, Gauthier S, Korczyn A, Lees R, Litvan I, Mizuno Y, McKeith IG, Olanow W, Poewe W, Sampaio C, Tolosa E, Emre M. Diagnostic procedures for Parkinson’s Disease Dementia : recommendations from the Movement Disorders Society rask force. Movement Disorders, 22, 2314-2324, 2007. MEDLINE link to this publication
Ferreri F, Agbokou C, Gauthier S. Effets cardio-vasculaires des inhibiteurs de la cholinesterase dans la maladie d’Alzheimer. Revue Neurologique, 163, 968-974, 2007. MEDLINE link to this publication
Peters KR, Rockwood K, Black SE, Hogan DB, Gauthier S, Loy-English I, Hsiung GYR, Jacova C, Kertesz A, Feldman H. Neuropsychiatric symptom clusters and functional disability in cognitively-impaired-not-demented individuals. American Journal of Geriatric Psychiatry, 15. Published on line October 10th 2007. MEDLINE link to this publication
Rockwood K, Moorhouse PK, Song X, MacKnight C, Gauthier S, Kertesz A, Montgomery P, Black S, Hogan DB, Guzman A, Bouchard R, Feldman H. Disease progression in vascular cognitive impairment: cognitive, functional and behavioral outcomes in the Consortium to Investigate Vascular impairment of Cognition (CIVIC) cohort study. Journal of Neurological Sciences, 252, 106-112, 2007. MEDLINE link to this publication
Herrmann N, Gauthier S, Lysy PG. Clinical practice guidelines for severe Alzheimer’s disease. Alzheimer’s & Dementia, 3, 385-397, 2007. MEDLINE link to this publication
Vellas B, Andrieu S, Cantet C, Dartigues JF, Gauthier S. Long-term changes in ADAS-cog: what is clinically relevant for disease-modifying trials in Alzheimer? Journal of Nutrition, Health & Aging, 11, 338-341, 2007. MEDLINE link to this publication
Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: an open-label, multicenter study in patients with Alzheimer’s disease. International Journal of Geriatric Psychiatry, 22, 806-812, 2007. MEDLINE link to this publication
Aisen P, Gauthier S, Vellas B, Briand R, Saumier D, Laurin J, Garceau D. Alzhemed: a potential treatment for Alzheimer’s disease. Currrent Alzheimer Research, 4, 473-478, 2007.
Gauthier S, Thal LL, Rossor MN. Future diagnosis and management of Alzheimer’s disease. In Clinical Diagnosis and Management of Alzheimer’s Disease, S. Gauthier [Ed], Informa Health Care, Abingdon, UK, 379-382, 2007.
Gauthier S, Erkinjutti T, Rockwood K. Vascular dementia. In Therapeutic Strategies in Dementia. CW Ritchie, D Ames, CL Masters, J Cummings [Eds], Clinical Publishing, Oxford, 273-286, 2007.
Gauthier S, Poirier J. Maladie d’Alzheimer. In “Précis de Gériatrie“, M. Arcand & R. Hébert, Eds, Edisem Inc., Montréal, 257-266, 2007.
Gauthier S, Poirier J. Survol des facteurs g/n/tiques et de quelques enjeux éthiquers liés à la maladie d’Alzheimer. L’Observatoire de la génétique, www.ircm.qc.ca/bioéthique/obsgenetique, Fev/Mars 2007.
Gauthier S, Outcomes for assessment of symptomatic and stabilization /disease modifying treatments. Canadian Journal of Neurological Sciences, 34, Suppl 1, S23-26, 2007. MEDLINE link to this publication
Camicioli R, Gauthier S. Clinical trials in Parkinson’s disease and Dementia with Lewy Bodies. Canadian Journal of Neurological Sciences, 34, Suppl 1, S109-117, 2007. MEDLINE link to this publication
Gauthier S, Juby A, Rehel B, Schecter R. EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer’s disease. International Journal of Clinical Practice, 61, 886-895, 2007. MEDLINE link to this publication
Katona C, Livingston G, Cooper C, Ames D, Brodaty H, Chiu E on behalf of the Consensus Group. International Psychogegriatric Association consensus statement on defining and measuring treatment benefits in dementia. International Psychogeriatrics, 19, 345-354, 2007. MEDLINE link to this publication
Gauthier S. Pharmacotherapy of Alzheimer’s disease. Current and future perspectives. European Pharmacotherapy, in press.
Erkinjuntti T, Román G, Gauthier S. Treatment of vascular dementia – evidence from clinical trials with cholinesterase inhibitors. J Neurological Sciences. MEDLINE link to this publication
Blair M, Kertesz A, Davis-Faroque N, Hsiung GYR, Black SE, Bouchard RW, Gauthier S, Guzman DA, Hogan DB, Rockwood K, Feldman H. Behavioral measures in frontotemporal lobar degeneration and other dementias: the utility of the Frontal Behavioral Inventory and the NeuroPsychiatric Inventory in a national cohort study. Dementia and Geriatric Cognitive Disorders, 23, 406-415, 2007.MEDLINE link to this publication
Ferreri F, Agbokou C, Gauthier S. Effets cardio-vasculaires des inhibiteurs de la cholinesterase dans la maladir d’Alzheimer. Revue Neurologique, in press.
Gauthier S. Trial designs and outcomes to monitor novel therapeutics in Alzheimer’s disease. In Pharmaceutical and Mechanisms in Alzheimer’s Therapeutics, AC Cuello [Ed], Springer, New York, in press.
King P, Song X, Rockwood K, MacKnight C, Gauthier S, Kertesz A, Montgomery P, Black S, Hogan DB, Guzman A, Bouchard R, Feldman H. Disease progression in vascular cogntive impairment: cognitive, functional and behavioural outcomes in the Consortium to Investigate Vascular Impairment of Cognition (CIVC) cohort study. Journal of the Neurological Sciences, in press.
Belleville S, Chertkow H, Gauthier S. Working memory and control of attention in persons with Alzheimer’s disease and mild cognitive impairment. Neuropsychology, 21, 458-469, 2007. MEDLINE link to this publication
Emre M, Aarsland D, Brown R, Burn DJ, Duykaerts C, Mizuno Y, Broe GA, Cummings J, Dickson DW, Gauthier S, Goldman J, Goetz C, Korczyn A, Lees A, Levy R, Litvan I, McKeith I, Olanow W, Poewe W, Quinn N, Sampaio C, Tolosa E, Dubois B. Clinical diagnostic criteria for dementia associated with Parkinson’s disease. Movement Disorders, 22, 1689-1707, 2007. MEDLINE link to this publication
Dubois B, Feldman H, Jacova C, DeKosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P. Research criteria for the diagnosis of Alzheimer’s disease: revisiting of the NINCDS-ADRDA criteria. Lancet Neurology, 6, 734-746, 2007. MEDLINE link to this publication
Seow D, Gauthier S. Pharmacotherapy of Alzheimer’s Disease. Canadian Journal of Psychiatry, 52, 620-629, 2007. MEDLINE link to this publication
Belleville S, Bherer L, Lepage E, Chertkow H, Gauthier S. Task switching capacities in persons with Alzheimer’s disease and mild cognitive impairment. Brain, submitted.
Winblad B, Gauthier S, Scinto L, Feldman H, Wilcock GK, Truyen L, Wang D, Brashear HR, Nye JS and the GAL-INT-11/18 Study group. Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, submitted.
Hsiung GYR, Alipour S, Jacova C, Grand J, Gauthier S, Black SE, Bouchard RW, Kertesz A, Loy-English I, Hogan DB, Rockwood K, Feldman H. Transitions from CIND to Alzheimer’s disease: an analysis of changes in functional abilities. Neurology, submitted.
Poirier J, Gauthier S. Pharmacogenomics and the treatment of sporadic Alzheimer’s disease: a decade of progress. Pharmacogenomics, submitted.
Published Abstracts
Gauthier S. Treatment options for Alzheimer’s disease. Neurodegenerative Diseases, 4 (suppl 1), 102, 2007.
Aisen P, Gauthier S, Briand R, Saumier D, Soulban G, Garceau D. A Phase III study of the efficacy, safety and disease modification effect of tramiprosate in mild to moderate Alzheimer’s disease. Alzheimer’s & Dementia, 3 (Suppl 2), S197, 2007.
Gauthier S, Aisen P, Vellas B, Briand R, Saumier R, Soulban G, Laurin J, Garceau D. The efficacy of tramiprosate in the treatment of mild to moderate Alzheimer’s disease: results of an 18-month Phase III trial. Journal of Neurology, 254 (Suppl 3), 11, 2007.
Gauthier S, Cummings JL, Loft H. Specific benefits of memantine on behavioural symptoms in patients with moderate to severe Alzheimer’s disease. European Journal of Neurology, 14 (Suppl 1), 49, 2007.
Gauthier S. The clinical relevance of symptomatic benefits of memantine. European Journal of Neurology, 14 (Suppl 1), 323, 2007.
Gauthier S. New treatments for dementia. International Psychogeriatrics, 19, (Suppl 1), 10-11, 2007
Gauthier S. Trial designs in Subjective Cognitive Impairment studies. International Psychogeriatrics, 19, (Suppl 1), 56, 2007.
Belleville S, Gilbert B, Fontaine F, Mellah S, Clement F, Blanchet S, Caza N, Gauthier S. Episodic memory training in persons with Mild Cognitive impairment. International Psychogeriatrics, 19, (Suppl 1), 68.
Gauthier S, Cummings J, Loft H. Specific benefits of memantine on behavioural symptoms in patients with moderate to severe Alzheimer’s disease. Canadian Journal of Geriatrics, 10, 105, 2007.
Bélanger S, Belleville S, Gauthier S. Inhibition deficits in persons with Mild Cognitive impairment”study with an adapted version of the Stroop paradigm. Canadian Journal of Geriatrics, 10, 109, 2007.
Gauthier S, Dalziel W, Keren R, Juby A, Rehel B, Schecter R. EXPLORE: improvements in symptoms of early AD following 12 months of treatment with rivastigmine. Canadian Journal of Geriatrics, 10, 113, 2007.
Books and Educational Material
Clinical Diagnosis and Management of Alzheimer’s Disease. Gauthier S (Ed), Informa Healthcare, London, 2007 (3rd edition).
2006 Academic Year
Articles:
Saull-McCaig S, Pacheco R, Kozak P, Gauthier S, Hahn R. Implementing MOE/MAR: balancing project management with change management., Healthc Q. 2006;10 Spec No:27-38, 4. MEDLINE link to this publication
Ferreri F, Agbokou C, Gauthier S. Recognition and management of neuropsychiatric complications in Parkinson's disease. CMAJ. 2006 Dec 5;175(12):1545-52. Review.MEDLINE link to this publication
Ferreri F, Agbokou C, Gauthier S. Cognitive dysfunctions in schizophrenia: potential benefits of cholinesterase inhibitor adjunctive therapy. J Psychiatry Neurosci. 2006 Nov;31(6):369-76. MEDLINE link to this publication
Touchon J, Portet F, Gauthier S, Prevention trials in Alzheimer disease: One step forward? Neurology. 2006 Nov 14;67(9 Suppl 3):S21-2. MEDLINE link to this publication
Gauthier S, Juby A, Morelli L, Rehel B, Schecter R; EXTEND Investigators., A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study. Curr Med Res Opin. 2006 Nov;22(11):2251-65. MEDLINE link to this publication
Lemieux V, Gauthier S, Branda NR., Selective and sequential photorelease using molecular switches., Angew Chem Int Ed Engl. 2006 Oct 20;45(41):6820-4. MEDLINE link to this publication
Gagnon JF, Petit D, Fantini ML, Rompre S, Gauthier S, Panisset M, Robillard A, Montplaisir J. , REM sleep behavior disorder and REM sleep without atonia in probable Alzheimer disease., Sleep. 2006 Oct 1;29(10):1321-5. MEDLINE link to this publication
Gauthier S., Treatment success in Alzheimer's disease. J Nutr Health Aging. 2006 Sep-Oct;10(5):416. MEDLINE link to this publication
Belleville S, Gilbert B, Fontaine F, Gagnon L, Menard E, Gauthier S, Improvement of episodic memory in persons with mild cognitive impairment and healthy older adults: evidence from a cognitive intervention programme. Dement Geriatr Cogn Disord. 2006;22(5-6):486-99. Epub 2006 Oct 16. MEDLINE link to this publication
Gauthier S, Herrmann N, Ferreri F, Agbokou C. , Use of memantine to treat Alzheimer's disease. CMAJ. 2006 Aug 29;175(5):501-2. No abstract available. Erratum in: CMAJ. 2006 Sep 26;175(7):777. Agokou, Catherine [corrected to Agbokou, Catherine]. MEDLINE link to this publication
Hudon C, Belleville S, Souchay C, Gely-Nargeot MC, Chertkow H, Gauthier S, Memory for gist and detail information in Alzheimer's disease and mild cognitive impairment., Neuropsychology. 2006 Sep;20(5):566-77. MEDLINE link to this publication
Zambelli T, Goudeau S, Lagoute J, Gourdon A, Bouju X, Gauthier S, Molecular self-assembly of jointed molecules on a metallic substrate: from single molecule to monolayer., Chemphyschem. 2006 Sep 11;7(9):1917-20. MEDLINE link to this publication
Abeguile F, Boudesocque-Dubois C, Clarisse JM, Gauthier S, Saillard Y., Linear perturbation amplification in self-similar ablation flows of inertial confinement fusion. Phys Rev Lett. 2006 Jul 21;97(3):035002. Epub 2006 Jul 21.MEDLINE link to this publication
Gauthier S, Cholinesterase inhibitors in late-stage Alzheimer's disease.
Lancet Neurol. 2006 Jun;5(6):468-9. MEDLINE link to this publication
de Poulin CL, Gelinas I, Gauthier S, Dayton D, Liu L, Rossignol M, Sampalis J, Dastoor D., Reliability and validity of the Safety Assessment Scale for people with dementia living at home. Can J Occup Ther. 2006 Apr;73(2):67-75. MEDLINE link to this publication
Garcia Diaz BE, Gauthier S, Davies PL., Ca2+ dependency of calpain 3 (p94) activation. Biochemistry. 2006 Mar 21;45(11):3714-22. MEDLINE link to this publication
Peters KR, Rockwood K, Black SE, Bouchard R, Gauthier S, Hogan D, Kertesz A, Loy-English I, Beattie BL, Sadovnick AD, Feldman HH. , Characterizing neuropsychiatric symptoms in subjects referred to dementia clinics. Neurology. 2006 Feb 28;66(4):523-8. MEDLINE link to this publication
Gauthier S., Managing discontinuation syndrome in patients with dementia.
J Psychiatry Neurosci. 2006 Jan;31(1):72. MEDLINE link to this publication
Chouinard S, Tessier M, Vernouillet G, Gauthier S, Labrie F, Barbier O, Belanger A., Inactivation of the pure antiestrogen fulvestrant and other synthetic estrogen molecules by UDP-glucuronosyltransferase 1A enzymes expressed in breast tissue., Mol Pharmacol. 2006 Mar;69(3):908-20. Epub 2005 Dec 8. MEDLINE link to this publication
Feldman H, Gauthier S, Chertkow H, Conn DK, Freedman M, MacKnight C for the 2nd Conference on Antidementia Guidelines. Canadian guidelines for the development of antidementia therapies: a conceptual summary. Canadian Journal of Neurological Sciences, 33, 6-26, 2006. MEDLINE link to this publication
Gauthier S, Reisberg B, Zaudig M, Petersen RC, Ritchie K, Broich K, Belleville S, Brodaty H, Bennett D, Chertkow H, Cummings JL, de Leon M, Feldman H, Ganguli M, Hampel H, Scheltens P, Tierney MC, Whitehouse P, Winblad B; International Psychogeriatric Association Expert Conference on mild cognitive impairment. Mild cognitive impairment. Lancet. 2006 Apr 15;367(9518):1262-70. MEDLINE link to this publication
Gauthier S. Clinical features of severe dementia: function. In “Severe Dementia”. A Burns, B Winblad (Eds). John Wiley & Sons, Ltd., 117-121, 2006.
Rockwood K, Black SE, Song X, Hogan DB, Gauthier S, MacKnight C, Vandorpe R, Guzman A, Montgomery P, Kertesz A, Bouchard RW, Feldman H., Clinical and radiographic subtypes of vascular cognitive impairment in a clinic-based cohort study. J Neurol Sci. 2006 Jan 15;240(1-2):7-14. Epub 2005 Oct 5. MEDLINE link to this publication
Hudon C, Belleville S, Souchay C, Gély-Nargeot MC, Chertkow H, Gauthier S. Memory for gist and detail information in Alzheimer's disease and mild cognitive impairment. Neuropsychology. 2006 Sep;20(5):566-77. MEDLINE link to this publication
Gagnon JF, Petit D, Fantini ML, Rompré S, Gauthier S, Panisset M, Robillard A, Montplaisir J. , REM sleep behavior disorder and REM sleep without atonia in probable Alzheimer disease. Sleep. 2006 Oct 1;29(10):1321-5. MEDLINE link to this publication
Hsiung GYR, Donald A, Grand J, Black SE, Bouchard RW, Gauthier S, Guzman DA, Hogan DB, Kertesz A, Rockwood K, Feldman H. Outcome of cognitively impaired not demented (CIND) at 2-years in the Canadian Cohort Study of Cognitive Impairment and Related Dementias (ACCORD) study. Dement Geriatr Cogn Disord. 2006;22(5-6):413-20. Epub 2006 Sep 11. MEDLINE link to this publication
Published Abstracts
Gauthier S. New data on the clinical relevance of BuChE in the progression of MCI and established dementia. Neurobiology of Aging, 27 (Suppl 1), S8, 2006.
Gauthier S. Translating results from clinical research into healthcare policies. Neurobiology of Aging, 27 (Suppl 1), S8, 2006.
Gauthier S. Long term treatment of Alzheimer’s disease. Alzheimer’s & Dementia, 2 (Suppl 1), S1-S2, 2006.
Gauthier S, Cooper J, Loft H. Specific benefits of memantine on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Alzheimer’s & Dementia, 2 (Suppl 1), S370, 2006.
2005 Academic Year
Articles:
Zambelli T, Lagoute J, Villagomez Ojeda CJ, Coudret C, Gauthier S., Tailoring the mobility of a 3D molecule adsorbed on a metal surface. J Phys Chem B Condens Matter Mater Surf Interfaces Biophys. 2005 Aug 4;109(30):14266-9. MEDLINE link to this publication
Gauthier S. Drugs for Alzheimer’s disease and related dementias. British Medical Journal, 330, 857-858, 2005. MEDLINE link to this publication
Gauthier S. The clinical significance of the overlap between dementia and vascular risk factors. Geriatrics & Aging, 8 (Suppl), 4-7, 2005.
Gauthier S. The use of galantamine in mixed and vascular dementia. Geriatrics & Aging, 8 (Suppl), 11- 15, 2005.
Gauthier S, Galasko D. How to translate results of randomized clinical trials into clinical practice for the care of persons with Alzheimer’s disease? In “Research Advances in Alzheimer Disease and Related Disorders 2004”. Khalid Iqbal, Bengt Winblad (Eds). Alzheimer’s Association, Chicago, USA, 2005.
Labrie F, Luu-The V, Calvo E, Martel C, Cloutier J, Gauthier S, Belleau P, Morissette J, Levesque MH, Labrie C. , Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. J Endocrinol. 2005 Feb;184(2):427-33. MEDLINE link to this publication
Gauthier S, Wirth Y, Möbius HJ. Effects of memantine on behavioural symptoms in Alzheimer’s disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomized, controlled studies. International Journal of Geriatric Psychiatry, 20; 459-464, 2005. MEDLINE link to this publication
Pare ME, Gauthier S, Landry S, Sun J, Legault E, Leclerc D, Tanaka Y, Marriott SJ, Tremblay MJ, Barbeau B., A new sensitive and quantitative HTLV-I-mediated cell fusion assay in T cells., Virology. 2005 Aug 1;338(2):309-22. MEDLINE link to this publication
Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM, and the Donepezil MSAD Study Investigators Group. Efficacy and safety of donepezil in patients with more severe Alzheimer’s disease: a subgroup analysis from a randomized, placebo-controlled trial. International Journal of Geriatric Psychiatry, 20, 559-569, 2005. MEDLINE link to this publication
Gauthier S, Touchon J. , Mild cognitive impairment is not a clinical entity and should not be treated. Arch Neurol. 2005 Jul;62(7):1164-6; discussion 1167. MEDLINE link to this publication
Gauthier S. Pharmacotherapy of amnestic mild cognitive impairment: lessons from the Memory Impairment Study. Aging Health, 1, 37-38, 2005.
Gauthier S. Alzheimer’s disease: the benefits of early treatment. European Journal of Neurology 12 (Suppl 3), 11-16, 2005. MEDLINE link to this publication
Gauthier S, McKeith IG. Classification and diagnostic criteria for dementia with Lewy bodies. In “Dementia with Lewy Bidies”, J. O’Brien, I. McKeith, D. Ames, E. Chiu (Eds.), Taylor & Francis, 27-31, 2005.
Gauthier S, Cloutier J, Dory YL, Favre A, Mailhot J, Ouellet C, Schwerdtfeger A, Merand Y, Martel C, Simard J, Labrie F. , Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution. J Enzyme Inhib Med Chem. 2005 Apr;20(2):165-77. MEDLINE link to this publication
McKeith IG, Gauthier S. Pharmacological treatment of dementia with Lewy bodies. In “Dementia with Lewy Bidies”, J. O’Brien, I. McKeith, D. Ames, E. Chiu (Eds.), Taylor & Francis, 183-192, 2005.
Gauthier S, MacKnight C. Clinical trial designs and endpoint selection. In “Trial designs and outcomes in dementia therapeutic research”, K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 37-44, 2005.
Gauthier S. Functional outcomes. In “Trial designs and outcomes in dementia therapeutic research”, K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 113-118, 2005.
Camicioli R, Gauthier S. Guidelines for randomized clinical studies in Parkinson’s disease in Parkinson’s disease with dementia and dementia with Lewy bodies. In “Trial designs and outcomes in dementia therapeutic research”, K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 165-175, 2005
Rockwood K, Gauthier S. Conclusions: lessons from clinical trials in dementia. In “Trial designs and outcomes in dementia therapeutic research”, K. Rockwood, S. Gauthier (Eds.), Taylor & Francis, 285-295, 2005.
Gauthier S. Trial designs. In “Dementia”, 3rd edition, A. Burns, J. O’Brien, D. Ames (Eds), Hodder Arnold, London, 522-525, 2005.
Vellas B, Gauthier S, Allain H et al. Consensus statement on dementia of Alzheimer type in the severe stage. Journal of Nutrition, Health and Aging, 9, 330-338, 2005.
Perras C, Shukla VK, Lessard C, Skidmore B, Bergman H, Gauthier S. Cholinesterase inhibitors for Alzheimer’s disease: a systematic review of randomized controlled trials. [Technology report no 58]. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2005.
Gauthier S. Profil actuel des consultations mémoire au Canada et besoins futurs. Dementiae, 3, 93-100, 2005.
Bhanji NH, Gauthier S, Emergent complications following donepezil switchover to galantamine in three cases of dementia with Lewy bodies., J Neuropsychiatry Clin Neurosci. 2005 Fall;17(4):552-5. MEDLINE link to this publication
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien J, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz C, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria R, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee V, Lees A, Litavan I, Londos E, Lopez O, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz J, Trojanowski J, Yamada M, for the Consortium on DLB. Dementia with Lewy Bodies: Diagnosis and Management. Third Report of the DLB Consortium. Neurology, 65, 1863-1872, 2005. MEDLINE link to this publication
Touchon J, Gauthier S. Prevention trials in AD: one step forward? Neurology, in press.
Gauthier S. Pharmacotherapy of Alzheimer’s disease. Current and future perspectives. European Pharmacotherapy, in press.MEDLINE link to this publication
Gauthier S. Alzheimer’s disease – Clinical. Encyclopedia of Aging, 4th Edition. Springer Publishing Company, NY, in press.
Gauthier S, Vellas B, Farlow M, Burn D. Aggressive course of disease in dementia. Alzheimer’s & Dementia, in press.
Turcotte K, Gauthier S, Tuite A, Mullick A, Malo D, Gros P. A mutation in the Icsbp1 gene causes susceptibility to infection and a chronic myeloid leukemia-like syndrome in BXH-2 mice. J Exp Med. 2005 Mar 21;201(6):881-90. MEDLINE link to this publication
Erkinjuntti T, Roman G, Gauthier S., Treatment of vascular dementia--evidence from clinical trials with cholinesterase inhibitors. J Neurol Sci. 2004 Nov 15;226(1-2):63-6. MEDLINE link to this publication
Gauthier S, Poirier J. Maladie d’Alzheimer. In “Précis de Gériatrie“, Marcel Arcand, éditeur, in press.
Published Abstracts
Moebius HJ, Wirth Y, Gauthier S. Memantine: behavioural benefits for moderate to severe Alzheimer’s patients. Neurology 64 (Suppl 1), A104, 2005.
Feldman H, Gauthier S, Hecker J, Vellas B, Ieni J, Xu Y, Schwam E. Treatment benefits of donepezil in patients with severe Alzheimer’s disease and their caregivers. Neurology 64 (Suppl 1), A105, 2005.
Galasko DR, Gauthier S, Bennett D, Sano M, Kaye J, Marson D, Peterson R. Impairment of activities of daily living in patients with amnestic Mild Cognitive Impairment in an ADCS randomized clinical trial. Neurology 64 (Suppl 1), A144, 2005.
Gauthier S. Designs and outcomes for studies to establish the efficacy of cognitive training. Int Psychogeriatrics 17 (Suppl 2), 69-70, 2005.
Belleville S, Gilbert B, Melah S, Fontaine S, Blanchet S, Gauthier S. Cognitive improvement and neural substrate of memory intervention in persons with mild cognitive impairment. Int Psychogeriatrics 17 (Suppl 2), 70, 2005.
Gauthier S, Wirth Y, Moebius HJ. Positive effects of memantine treatment in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatrics 17 (Suppl 2), 206, 2005.
Gilbert B, Belleville S, Mellah S, Gauthier S. Effect of a multifactorial memory intervention on the subjective complaint of persons with mild cognitive impairment. Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
Hudon C, Belleville S, Lepage E, Gauthier S, Chertkow H. Characterization of the episodic memory impairment in Alzheimer’s disease and mild cognitive impairment. Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
Gauthier S. Memantine effects on behavior and activities of daily living: benefits for patients and caregivers. Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
Gauthier S. Does rapid decline dementia have a genetic basis? Int Psychogeriatrics 17 (Suppl 2), 241, 2005.
Gauthier S, Keren R, Juby A, Morelli L, Schecter R. EXACT: high prevalence of mood and behavior symptoms in Alzheimer’s disease are improved following 6 months of treatment with rivastigmine. Geriatrics Today 8, 117-118, 2005.
Vanier M, Gauthier S, Gélinas I, Lazure P, Audet T, Lamoureux J, Dobbs A, Mazer B, Demers L, Brouwer W. Usefulness of a driving simulator for the assessment of drivers with early-stage Alzheimer’s disease. Geriatrics Today 8, 121, 2005.
Gauthier S. Translating results from clinical research into healthcare policies. Neurobiology of Aging 27 (S1), S9, 2006.
Books and educational material
Alzheimer’s Disease and Related Disorders vol 5. Gauthier S, Scheltens, P, Cummings J (Eds). Martin Dunitz/Taylor & Francis, London, 2005.
Designs and outcomes in dementia therapeutic research. K. Rockwood, S. Gauthier. Taylor & Francis, 2005.
2004 Academic Year
Full articles
McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda J, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez O, Machado J, O’Brien J, Palyfer J, Reid W on behalf of the IPA Special Expert Meeting. Dementia with Lewy bodies. Lancet Neurology, 3, 19-28, 2004. MEDLINE link to this publication
Petersen RC, Grundman M, Ferris SH, Thomas RG, Aisen P, Bennett D, Foster N, Jack C, Galasko D, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schulz AN, Schafer K, Mulnard R, van Dyke C, Mintzer J, Zamrini EY, Cahn D, Thal LJ, and the Alzheimer Disease Cooperative Study. The ADCS clinical trial of vitamin E and donepezil HCl (Aricept) to delay clinical progression from mild cognitive impairment (MCI) to Alzheimer`s disease (AD): trial design and subjects baseline characteristics. Archives of Neurology, 61, 59-66, 2004.
Gauthier S. Traitement de la maladie d`Alzheimer: aspects méthodologiques généraux. Revue Neurologique, 160, 261-264, 2004.
Erkinjuntti T, Román G, Gauthier S, Feldman H, Rockwood K. Emerging therapies for vascular dementia and vascular cognitive impairment. Stroke 35, 1010-1017, 2004.
Erkinjuntti T, Roman G, Gauthier S. Treatment of vascular dementia-evidence from clinical trials with cholinesterase inhibitors. Neurol Res. 2004 Jul;26(5):603-5. MEDLINE link to this publication
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V for the Donepezil MSAD Study Investigators Group. Economic evaluation of donepezil in moderate to severe Alzheimer’s disease. Neurology. 2004 Aug 24;63(4):644-50. MEDLINE link to this publication
Blanchet S, Belleville S, Phillips N, Mellah S, Gauthier S, Chertkow H. Electrophysiological study of working memory in mild cognitive impairment patients. Brain Cogn. 2004 Mar;54(2):144-5. MEDLINE link to this publication
Gauthier S. The benefits of apolipoprotein E epsilon 4 screening to research. Canadian Medical Association Journal 171, 881, 2004. MEDLINE link to this publication
Parkinson Study Group. Levodopa and the rate of progression of Parkinson disease, the ELLDOPA study. New England Journal of Medicine, 351, 2498-2508, 2004.
Gauthier S. Pharmacotherapy of mild cognitive impairment. Dialogues in Clinical Neurosciences, 6, 391-395, 2004.
Book chapters
Gauthier S, Touchon J. Subclassification of mild cognitive impairment in research and in clinical practice. Alzheimer’s Disease and Related Disorders Annual 2004, (S. Gauthier, P. Scheltens, JL Cummings, Eds), Martin Dunitz, London, 61-69, 2004.
Books edited
Alzheimer’s Disease and Related Disorders Annual 2004. Gauthier S, Scheltens P, Cummings J (Eds). Martin Dunitz, London, 2004.
Alzheimer Disease. Neuropsychology and Pharmacology. Emilien G, Durlach C, Minaker KL, Winblad B, Gauthier S, Maloteaux JM. Birkäuser Publishers Ltd, Basel, 2004.
Published abstracts
Gauthier S. What can we expect from add-on and survival designs in order to establish disease progression? Neurobiology of Aging, 25 (Suppl 1), S11, 2004.
Gauthier S. Behavioural benefit by memantine treatrment in modetate to severe Alzheimer. International Journal of Neuropsychopharmacology, 7 (Suppl 1), S380, 2004.
Möbius H, Stöffler A, Wirth Y, Gauthier S. Memantine positively influences behavior in moderate to severe Alzheimer’s disease. Neurobiology of Aging 25 (Suppl 2), S18, 2004.
Gauthier S. How to translate results of randomized clinical trials into clinical practice? Neurobiology of Aging 25 (Suppl 2), S92, 2004.
Gauthier S et al. A Canadian study on the genetics of late-onset Alzheimer’s disease associations: “GenADA”. Neurobiology of Aging 25 (Suppl 2), S138, 2004.
Shah SN, Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam E, Leaderer M. Pharmacoeconomic benefits of donepezil treatments in severe Alzheimer’s disease. Neurobiology of Aging 25 (Suppl 2), S208, 2004.
Fornazzari L, Nadkarni S, Surh L, Newton R, Salvarrey A, Apanasiewicz N, Miranda D, St George Hyslop P, Borrie M, Feldman H, Gauthier S et al. Inter-rater reliability of neuropsychological assessments used in the Canadian study on genetics of Alzheimer’s disease associations (GenADA). Neurobiology of Aging 25 (Suppl 2), S323, 2004.
Gauthier S, Wirth Y, Stöffler A, Möbius HJ. Memantine has positive effects on behavior in moderate to severe Alzheimer’s disease. European Journal of Neurology 11 (Suppl 2), 188, 2004.
Books and Educational Material
Alzheimer Disease. Neuropsychology and Pharmacology. Emilien G, Durlach C, Minaker KL, Winblad B, Gauthier S, Maloteaux JM. Birkäuser Publishers Ltd, Basel, 2004.
2003 Calendar Year
O'Brien JT, Erkinjuntti T, Reisberg B, Roman G, Pantoni L, Bowler JV, Ballard C, DeCarli C, Gorelick PB, Rockwood K, Burns A, Gauthier S, DeKosky ST, Sawada T. Vascular Cognitive Impairment. Lancet Neurology, 2, 89-98, 2003. MEDLINE link to this publication
Law A, Gauthier S, Quirion R. Alteration of nitric oxide synthase activity in young and aged apolipoprotein E-deficient mice. Neurobiology of Aging, 24, 187-190, 2003. MEDLINE link to this publication
Gauthier S. Clinical aspects of Alzheimer’s disease. In Clinical management of early Alzheimer’s disease. Mulligan R., Van der Linden M., Juillerat A.C. (eds), 21-34, 2003.
Feldman H, Gauthier S, Hecker J, Vellas B, Emir B, Mastey V, Subbiah P, The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer's disease, and the impact on caregiver burden. Journal of the American Geriatric Society, 51, 737-744, 2003. MEDLINE link to this publication
Gauthier S. Management of later stages of Alzheimer’s disease. Research and Practice in Alzheimer’s Disease, Vellas B, Winblad B, Grundman M, Fitten LJ, Feldman H, Giacobini E, Kurz A (Eds), vol 7, 146-149, 2003.
Rockwood K, Davis H, MacKnight C, Vandorpe R, Gauthier S, Guzman A, Montgomery P, Black S, Hogan DB, Kertesz A, Bouchard R, Feldman H. The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings. Canadian Journal of Neurological Sciences, 30, 237-243, 2003. MEDLINE link to this publication
Desrosiers RR, Bertrand Y, Nguyen QT, Demeule M, Gabathuler R, Kennard ML, Gauthier S, Béliveau R. Expression of multiple isoforms of melanotransferrin in human body fluids: relevance to Alzheimer's disease. Biochemical Journal, 374, 463-471, 2003. MEDLINE link to this publication
Allain H, Bentué-Ferrer D, Tribut O, Gauthier S, Michel BF, Drieu-La Rochelle C. Alzheimer’s disease : the pharmacological pathway. Fundamental & Clinical Pharmacology 17, 419-428, 2003. MEDLINE link to this publication
Feldman H, Levy AR, Hsiung GY, Peters KR, Donald A, Black SE, Bouchard RW, Gauthier S, Guzman DA, Hogan DB, Kertesz A, Rockwood K for the ACCORD Study Group. A Canadian Cohort study of cognitive impairment and Related Dementias (ACCORD). Study methods and baseline results. Neuroepidemiology, 22, 265-274, 2003. MEDLINE link to this publication
Gauthier S, Rockwood K. Does vascular MCI progress at a different rate than does amnestic MCI? Int Psychogeriatr. 2003;15 Suppl 1:257-9. MEDLINE link to this publication
2002 Calendar Year
Gauthier S. Advances in the pharmacotherapy of Alzheimer`s disease. Canadian Medical Association Journal, 166; 616-623, 2002. MEDLINE link to this publication
Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002 Apr 13;359(9314):1283-90. MEDLINE link to this publication
Law A. Zheng WH, Gauthier S, Quirion R. Alterations of nitric oxide synthase expression and activity in Alzheimer`s disease brains. Brain Aging, 2, 34-41, 2002.
Gauthier S. Diagnostic instruments to assess functional Impairment. In Evidence-based dementia practice. Qizilbask N, Schneider LS, Chui H, Tariot P, Brodaty H, Kaye J, Erkinjuntti T (Eds), Blackwell Science Ltd, Oxford, England, 101-105, 2002.
Sibley A, MacKnight C, Rockwood K, Fisk J, Gauthier S, Guzman DA, Hogan DB; Consortium to Investigate Vascular Impairment of Cognition.. The effect of living situation on the severity of dementia at diagnosis. Dementia and Geriatric Cognitive Disorder, 13, 40-45, 2002. MEDLINE link to this publication
Gauthier S, Gélinas I. Evaluation of daily activities in vascular cognitive impairment. In ‘Vascular Cognitive Impairment’, T. Erkunjutti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 411-416, 2002.
Ferris S, Gauthier S. Cognitive outcome measures in vascular dementia. In ‘Vascular Cognitive Impairment’, T. Erkunjutti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 395-400, 2002.
Rockwood K, Gauthier S, Erkinjuntti T. Prevention and treatment of vascular dementia. In ‘Vascular Cognitive Impairment’, T. Erkunjutti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 587-595, 2002.
Erkinjuntti T, Gauthier S. Vascular causes of cognitive impairment – the perspective. In ‘Vascular Cognitive Impairment’, T. Erkunjutti, S. Gauthier (Eds), Martin Dunitx Ltd, London, 643-651, 2002.
Panisset M, Gauthier S, Moessler H, Windisch M and the Cerebrolysin Study Group. Cerebrolysin in Alzheimer's Disease: a randomized, double-blind, placebo-controlled trial with a neurotropichic agent. Journal of Neural Transmission, 109, 1089-1104, 2002. MEDLINE link to this publication
Gauthier S, Grundman M. Alzheimer`s disease: trial designs to establish disease modification. In "Alzheimer's disease and related disorders Annual 2002", S. Gauthier, JL Cummings (eds), Martin Dunitz, London, 77-85, 2002.
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E, Emir B. The efficacy and safety of donepezil in patients with moderate to severe Alzheimer’s disease. Research and Practice in Alzheimer’s Disease, 6, 302-307, 2002.
Law A, O'Donnell J, Gauthier S, Quirion R. Neuronal and inducible nitric oxide synthase expressions and activities in the hippocampi and cortices of young adult, aged cognitively unimpaired, and impaired Long-Evans rats. Neuroscience, 112, 267-275, 2002. MEDLINE link to this publication
Gauthier S. Assessing the response of patients with Alzheimer`s disease to cholinesterase inhibitors. Geriatrics and Aging, 5, 23-24, 2002.
Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P; Donepezil MSAD Study Investigators' Group. Functional, cognitive and behavioural effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin. 2002;18(6):347-54. MEDLINE link to this publication
Gauthier S. Long-term efficacy of cholinesterase inhibitors. Brain Aging, 2, 9-22, 2002.
Pratt RD, Perdomo CA and the Donepezil VaD 307 and 308 Study Groups. Donepezil-treated patients with probable vascular dementia demonstrate cognitive benefits. Annals New York Academy of Sciences, 977, 513-522, 2002.
Gauthier S, Feldman H, Hecker J, Vellas B, Ames D, Subbiah P, Whalen E, Emir B. The Donepezil MSAD Study Investigators Group. Efficacy of donepezil on behavioural symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr. 2002 Dec;14(4):389-404. MEDLINE link to this publication
2001 Calendar Year
Gauthier S, Gauthier J, Dupin F, Panisset M. Comment déterminer l’aptitude du mandant? In ‘Les mandats en cas d’inaptitude: une panacée?, Service de la formation permanente du Barreau du Québec, Les Editions Yvon Blais Inc, Cowansville, 71-82, 2001.
Gauthier S. Alzheimer’s disease: current and future therapeutic perspectives. Prog Neuropsychopharmacol Biol Psychiatry. 2001 Jan;25(1):73-89. MEDLINE link to this publication
Patterson C, Gauthier S, Bergman H, Cohen C, Feighhtner JW, Feldman H, Grek A, Hogan D. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Canadian Journal of Neurological Sciences, 28 (Suppl 1), S3-S16, 2001. MEDLINE link to this publication
Chertkow H, Bergman H, Schipper HM, Gauthier S, Bouchard R, Fontaine S, Clarfield M. Assessment of suspected dementia, Canadian Journal of Neurological Sciences, 28 (Suppl 1), S28-S41, 2001.
Gauthier S, Ferris S. Outcome measures for probable vascular dementia and Alzheimer’s disease with cerebrovascular disease. Int J Clin Pract Suppl. 2001 May;(120):29-39. MEDLINE link to this publication
Wolfson C., Wolfson DB, Asgharian M, M’Lan CE, Ostbye T, Rockwood K, Hogan DB for the Clinical Progression of Dementia Study Group. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med. 2001 Apr 12;344(15):1111-6. MEDLINE link to this publication
Gauthier S. Muscarinic agonists. In ‘Alzheimer’s Disease and Related Disorders Annual 2001’, S. Gauthier, J. Cummings (eds), Martin Dunitz, London, 85-96, 2001.
Feldman H., Sauter A., Donald A., Gélinas I., Gauthier S, Torfs K., Parys W, Mehnert A. The Disability Assessment for Dementia scale: a 12-month study of functional ability in mild to moderate severity Alzheimer’s disease. Alzheimer Dis Assoc Disord. 2001 Apr-Jun;15(2):89-95. MEDLINE link to this publication
Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen W for the Donepezil MSAD Study Investigators Group. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease. Neurology, 57, 615-620, 2001.
Winblad B, Brodaty H, Gauthier S, Morris JC, Orgogozo JM, Rockwood K, Schneider L, Takeda M, Tariot P, Wilkinson D. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry. 2001 Jul;16(7):653-66. MEDLINE link to this publication
Law A, Gauthier S, Quirion R. Neuroprotective and neurorescuing effects of isoform-specific nitric oxide synthase inhibitors, nitric oxide scavenger, and antioxidant against beta-amyloid toxicity. Br J Pharmacol. 2001 Aug;133(7):1114-24. MEDLINE link to this publication
Wentzel C, Rockwood K, MacKnight C, Hachinski V, Hogan D, Feldman H, Ostbye T, Wolfson C, Gauthier S, Verreault R, McDowell I. Progression of impairment in patients with Vascular Cognitive Impairment without dementia. Neurology. 2001 Aug 28;57(4):714-6. MEDLINE link to this publication
Law A, Gauthier S, Quirion R. Say NO to Alzheimer’s disease : the putative links between nitric oxide and dementia of the Alzheimer type. Brain Res, Brain Res Rev. 2001 Mar;35(1):73-96.
Rockwood K, Black S, Gauthier S, Feldman H, Wentzell C. Clinical and neuroimaging findings in mixed dementia. Research and Practice in Alzheimer’s Disease, 5, 115-122, 2001. MEDLINE link to this publication
Tomossy GF, Weisstub DN, Gauthier S. Regulating ethical research involving cognitively impaired elderly subjects. Canada as a case study. In ‘Aging; Decisions at the End of Life’, DN Weisstub, DC Thomasma, S. Gauthier, GF Tomossy (Eds), Kluver Academic Publishers, Dordrecht – Boston – London, 227-254, 2001.
Gauthier S. Cholinergic adverse effects of cholinesterase inhibitors in Alzheimer's disease: epidemiology and management. Drugs Aging. 2001;18(11):853-62. MEDLINE link to this publication
2000 Calendar Year
Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. Neurology. 2000 Jan 25;54(2):447-51. MEDLINE link to this publication
Gauthier S. Impact of new therapies on the management of Alzheimer's disease. International Medical Journal 2000, 4-6, 2000.
Gauthier S. From bench to bedside: how to treat dementia. In Evidence & experience in Psychiatry: Dementia. Maj M, Sartorius N (eds), WPA Series, Wiley, 252-254, 2000.
Rockwood K, MacKnight C, Wentzel C, Black S, Bouchard R, Gauthier S, Feldman H, Hogan D, Kertesz A, and P. Montgomery for the CIVIC investigators. The diagnosis of "mixed" dementia in the Consortium for the Investigation of Vascular Inpairment of Cognition (CIVIC). Annals of the New York Academy of Sciences, 903, 522-528, 2000. MEDLINE link to this publication
1999 Calendar Year
Peer reviewed articles
Gauthier S. Managing expectations in the long-term treatment of Alzheimer's disease. Gerontology, 1999, vol. 45 (Supp.l 1), pp. 33-38.
Rösler M, Anand R, Cicin-Sain A, Gauthier S, Agid Y, Dal-Bianco P, Stahelin HB, Hartman R, Gharabawi M. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ. 1999 Mar 6;318(7184):633-8. MEDLINE link to this publication
Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Moller HJ, Rogers SL, Friedhoff LT. and the Donepezil Study Group. Donepezil in the treatment of Alzheimer's disease - Results from a multinational clinical trial. Dement Geriatr Cogn Disord 1999, vol. 10, pp. 237-244. MEDLINE link to this publication
Gray JA, Gauthier S. Stabilization approaches to Alzheimer's disease. Gauthier S (ed), Martin Dunitz, Publisher, London, 1999, pp. 269-278.
Gauthier S, Thal LJ, Rossor MN. The future diagnosis and management of Alzheimer's disease. Gauthier S (ed), Martin Dunitz, London, 1999, pp. 369-378.
O'Brien BJ, Goeree R, Hux M, Iskedjian M, Blackhouse G, Gagnon M, Gauthier S. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. J Am Geriatr Soc. 1999 May;47(5):570-8. MEDLINE link to this publication
Mendis T, Suchowersky O, Lang A, Gauthier S. Management of Parkinson's disease a review of current and new therapies. Can J Neurol Sci. 1999 May;26(2):89-103. MEDLINE link to this publication
Patterson C, Gauthier S, Bergman H, Cohen C, Feightner JW, Feldman H., Grek A., Hogan DB. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. Canadian Medical Association Journal 1999, vol. 160 (Suppl 12), S1-S15. MEDLINE link to this publication
Patterson C, Gauthier S, Bergman H, Cohen C, Feightner JW, Feldman H, Grek A., Hogan DB. Canadian Consensus Conference on Dementia: a physician's guide to using the recommendations. Canadian Medical Association Journal 1999, vol. 160, 1738-1742. MEDLINE link to this publication
Cohen C, Whitehouse P, Post SG, Gauthier S, Eberhart A, Leduc L. Ethical issues in Alzheimer disease: the experience of a national Alzheimer society task force. Alzheimer Dis Assoc Disord. 1999 Apr-Jun;13(2):66-70. MEDLINE link to this publication
Brodaty H., Dresser R, Eisner R, Erkunjuntti T, Gauthier S, Graham N, Jonker C, Sachs G, Whitehouse P. Alzheimer's Disease International and International Working Group for Harmonization of Dementia Drug Guidelines for research invol.ving human subjects with dementia. Alzheimer Disease and Associated Disorders, 1999, vol. 13, 71-79.
Issa AM, Gauthier S, Collier B. Enzyme activity and protein of multiple forms of choline acetyltransferase: effects of calyculin A and okadaic acid.
Neurochem Res. 1999 Aug;24(8):987-93. MEDLINE link to this publication
Issa AM, Gauthier S, Collier B. Effects of calyculin A and okadaic acid on acetylcholine release and subcellular distribution in rat hippocampal formation.
J Neurochem. 1999 Jan;72(1):166-73. MEDLINE link to this publication
Gauthier S. Do we have a treatment for Alzheimer's disease - yes. Archives of Neurology, 1999, vol. 56, 738-739.
Gélinas I, Gauthier L, McIntyre M, Gauthier S. Development of a functional measure for persons with Alzheimer's disease: the Disability Assessment of Dementia. American Journal of Occupational Therapy, 1999, vol. 53, 471-481. MEDLINE link to this publication
Gauthier S. Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. Expert Opinion Investigational Drugs, 1999, 8, 1511-1520.
Gauthier S. Démences: de l' épidémiologie aux nouvelles approches préventives. Dans L'année gérontologique 1999, 13, 95-97.
Gauthier S, Rockwood K, Gélinas I, Sykes L, Teunisse S, Orgogozo JM, Erkinjuntti T, Erzigkeit H, Gleeson M, Kittner B, Pontecorvo M, Feldman H, Whitehouse P. Outcome measures for the study of activities of daily living in vascular dementia. Alzheimer Disease and Associated Disorders, 1999, 13 (suppl. 3), S143-S147.
Koller WC, Hutton JT, Tolosa E, Capilldeo R and the Carbidopa /Levodopa Study Group. Immediate release and controlled-release carbidopa/levodopa in the treatment of Parkinson's disease: a 5-year multicenter study. Neurology, 1999, 53, 1012-1019.
Book Chapters and Educational Material
Gauthier S. Tacrine.hydrochloride In: Therapeutic Drugs, 2nd edition. C. Dollery (ed). 1999, pp. T1-T4.
Gauthier S, Byrne J, Byrne L. Research potential. In: Diagnosis and management of dementia: a manual for memory disorders teams. G.K. Wilcox, R.S. Bucks, K. Rockwood (eds). Oxford Medical Publications 1999, pp. 190-208.
Books
Alzheimer's disease in primary care. Gauthier S. Martin Dunitz, London, 1999 (2nd edition)
Clinical diagnosis and management of Alzheimer's disease. Gauthier S (ed), Martin Dunitz, London, 1999 (2nd edition).
1998 Calendar Year
Peer reviewed papers
Gauthier S. Prevention of Alzheimer's disease. Annales de Médecine Interne 1998, vol. 149, pp. 1-3.
Gauthier S. Treatment strategies for Alzheimer's disease. McGill Journal of Medicine 1998, vol. 3, pp. 149-152.
Gauthier S. Case report: clinical assessment of Alzheimer's disease and response to donepezil treatment. McGill Journal of Medicine 1998, vol. 3, pp. 153-155.
Beffert U, Bertrand P, Champagne D, Gauthier S, Poirier J. HSV-1 in brain and risk of Alzheimer's disease. The Lancet, 1998, vol. 352, p. 238. MEDLINE link to this publication
Fisk JD, Sadovnick AD, Cohen CA, Gauthier S, Dossetor J, Eberhart A, LeDuc L. Ethical guidelines of the Alzheimer Society of Canada. Canadian Journal of Neurological Sciences, 1998, vol. 25, pp. 242-248. MEDLINE link to this publication
Lakmache Y, Lassonde M, Gauthier S, Frigon JY, Lepore F. Interhemispheric disconnection syndrome in Alzheimer's disease. Proceedings National Academy of Sciences, 1998, vol. 95, pp. 9042-9046. MEDLINE link to this publication
Shoulson I, and the Parkinson Study Group. DATATOP: a decade of neuroprotective inquiry. Annals of Neurology 1998, vol. 44 (Supp.l 1), pp. S160-S166. MEDLINE link to this publication
Beffert U, Bertrand P, Champagne D, Gauthier S, Poirier J. Herpes simplex virus type 1 in brain, apolipoprotein E genotype and Alzheimer's disease. McGill Journal of Medicine, 1998, vol.4, pp.10-14.
Beffert U, Bertrand P, Champagne D, Gauthier S, Poirier J. HSV-1 in brain and risk of Alzheimer's disease. Lancet 1998, vol. 351, pp. 1330-1331. MEDLINE link to this publication
Hux MJ, O'Brien BJ, Iskedjian M, Goeree R, Gagnon M, Gauthier S. Relationship between severity of Alzheimer's disease and costs of caring. Canadian Medical Association Journal, 1998, vol. 159, pp. 457-465. MEDLINE link to this publication
Gauthier S. Clinical trials and therapy. Curr Opin Neurol. 1998 Oct;11(5):435-8. MEDLINE link to this publication
Qizilbash N, Whitehead A, Higgins J, Wilcock G, Schneider L, Farlow M for the Dementia Trialists' Collaboration. Cholinesterase inhibition for Alzheimer disease: a meta-analysis of the tacrine trials. Dementia Trialists' Collaboration. Journal of the American Medical Association, 1998, vol. 280, pp.1777-1782.
Gauthier S. Update on diagnostic methods, natural history and outcome variables in Alzheimer's disease. Dement Geriatr Cogn Disord , 1998, vol. 9 (supp.l 3), pp. 2-7.
Whitehouse P, Winblad B., Shostak D., Bhattacharja A., Brod M., Brodaty H., Dor A., Feldman H., Forette, F., Gauthier S, Hay J., Henke C., Hill S., Mastey V., Neuman P., O'Brien B., Pugner K., Sano M., Sawada T., Stone R., Wimo A. First International pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Alzheimer Disease and Associated Disorders, 1998, vol. 12, pp. 266-280.
Book Chapters
Gauthier S, Poirier, J. Achievements and unresolved issues. In: Pharmacotherapy of Alzheimer's disease. Gauthier, S. (ed), Martin Dunitz, London, 1998, pp. 151-159.
Gauthier S. Costs of diagnostic procedures. In: Health Economics of Dementia, Winblad B, Wimo A, Jonsson B, Karlsson G. (eds), Joh Wiley and Sons Ltd., 1998, pp. 269-273.
Gauthier S, Panisset M. Current diagnostic methods and outcome variables for clinical investigation of Alzheimer's disease. In: Ageing and Dementia, Jellinger, K., Fazekas, F., Windisch, M. (Eds), Springer Wien. New York, 1998, pp. 251-254.
Panisset M, Gauthier S. Outcome variables in research and in practice. In: Pharmacotherapy of Alzheimer's disease. Gauthier S. (Ed), Martin Dunitz, London, 1998, pp. 33-41.
Books
Pharmacotherapy of Alzheimer's disease. Gauthier S (ed). Martin Dunitz, London, 1998.
1997 Academic Year
Peer reviewed papers
Caramelli P, Poissant A, Gauthier S, Bellavance A, Gauvreau D, Lecours AR, Joanette Y. Educational level and neuropsychological heterogeneity in dementia of the Alzheimer type. Alzheimer Disease and Associated Disorders, 11, pp. 9-15, 1997. MEDLINE link to this publication
Pallister C, Jung S, Shaw I, Nalbantoglu J, Gauthier S, Cashman N. Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. Neurobiology of Aging 1997,vol. 18,pp.97-103.
MEDLINE link to this publication
Graham JE, Rockwood K, Beattie BL, Eastwood R, Gauthier S, Tuokko M, McDowell I. Prevalence and severity of cognitive impairment with and without dementia in an elderly population. The Lancet 1997, vol. 349, pp. 1793-1796.
MEDLINE link to this publication
Hasssaina F, Petit D, Nielsen T, Gauthier S, Montplaisir J. Quantitative EEG and statistical mapping of wakefulness and REM sleep in the evaluation of mild to moderate Alzheimer's disease. European Neurology 1997, vol. 37, pp., 219-224.
MEDLINE link to this publication
Gauthier S, Bodick N, Erzigkeit H, Feldman H, Geldmacher DS, Huff J, Mohs R, Orgogozo JM, Rogers S. Activities of daily living as an outcome measure in clinical trials of dementia drugs. Alzheimer Disease and Associated Disorders 1997, vol. 11 (suppl 3), pp. 6-7. MEDLINE link to this publication
Whitehouse P, Orgogozo JM, Becker RE, Gauthier S, Portercorvo M, Erzigkeit H, Rogers S, Mohs RC, Bodick N, Bruno G, Dal-Bianco P. Quality of life assessment in dementia drug development. Alzheimer Disease and Associated Disorders 1997, vol. 11 (suppl 3), pp. 56-60.
MEDLINE link to this publication
Bodick NC, Offen WW, Levey AI, Cutler NR, Gauthier S, Satlin A, Shannon HE, Tollefson GD, Murley DJ, Paul SM. Effects of xanomeline, a- selective muscarinic, receptor agonist, on cognitive function and behavioural symptoms in Alzheimer's disease. Archives of Neurology 1997, vol. 54, pp. 465-473. MEDLINE link to this publication
Gauthier S, Panisset M, Nalbantoglu J, Poirier J. Alzheimer's disease: current knowledge, management and research. Canadian Medical Association Journal 1997, vol. 157, pp. 1047 - 1052. MEDLINE link to this publication
Post SG, Beerman B, Brodaty H, Gaines A, Gauthier S, Geldmacher DS, Hill S, Hommer A, Rossor M, Whitehouse P, Winblad B. Ethical issues in dementia drug development. Alzheimer disease and associated disorders 1997, vol. 11 (suppl 3), pp. 26-28. MEDLINE link to this publication
Montplaisir J, Petit D, Masson H, Bédard MA, Decary A, Panisset M, Gauthier S, Rémillard E. Sleep and quantitative EEG in patients with progressive supranuclear palsy. Neurology 1997, vol. 49, pp. 999-1003.
MEDLINE link to this publication
Rockwood K, Beattie BL, Eastwood MR, Feldman H, Mohr E, Pryse-Phillips W, Gauthier S. A randomized, controlled trial of linopirdine in the treatment of Alzheimer's disease. Canadian Journal of Neurological Sciences 1997, vol. 24, pp. 140-145. MEDLINE link to this publication
Baumgarten M, Battista RN, Infante-Rivard C, Hanley JA, Becker R, Gauthier S. Use of physician services among family caregivers of elderly persons with dementia. Journal of Clinical Epidemiology 1997, vol. 50, pp. 1265-1272.
MEDLINE link to this publication
Books and Educational Material
Alzheimer's disease in primary care. Gauthier S, Burns A, Petit W. Martin Dunitz, London, 1997.
La enfermedad de Alzheimer en atencion primaria. Gauthier S, Burns A, Petit W, Bernejo F. (eds), Martin Dunitz, London, 1997.
La malattia di Alzheimer: une guida per il medico di base. Gauthier S, Amaducci L, Burns A, Pettit W. Martin Dunitz, London, 1997.
Alzheimer - demenz in der primärversorgung. Gauthier S, Burns A, Pettit W, Kurz A. Martin Dunitz, London, 1997.
La maladie d'Alzheimer en médecine générale. Gauthier S, Burns A, Pettit W. Martin Dunitz, London, 1997.
Birinci basamak sa lik hizmetlerinde Alzheimer hastali i. Gauthier S, Burns A. Pettit W. Martin Dunitz, London, 1997.
Book Chapters
Gauthier S, Poirier J. Neuroprotection in chronic neurologic disease - Alzheimer's disease. In: ANeuroprotection: fundamental and clinical aspects@. Bär, P.R., Beal, M.F., eds, Marcel Dekker Inc., New York, 1997, pp. 447-455.
|
